KPC Pharmaceuticals Inc
SSE:600422
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.04
23.78
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
KPC Pharmaceuticals Inc
KPC Pharmaceuticals Inc
Gross Profit
KPC Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
KPC Pharmaceuticals Inc
SSE:600422
|
Gross Profit
¥3.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
10%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Gross Profit
¥9.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Gross Profit
¥4.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
21%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Gross Profit
¥22.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Gross Profit
¥10.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Gross Profit
¥319.6m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
KPC Pharmaceuticals Inc
Glance View
KPC Pharmaceuticals Inc., founded in 1951, has cultivated a strong presence in the pharmaceutical industry, rooted in the rich herbal traditions of China. With its headquarters strategically located in Yunnan, a region renowned for its vast biodiversity, KPC leverages this unique advantage by integrating indigenous herbal knowledge into modern pharmaceuticals. The company has carved a niche for itself primarily through the production and distribution of traditional Chinese medicine. This approach not only honors the cultural heritage of its origins but also allows the company to capitalize on a growing global demand for alternative and complementary medical treatments. The blend of traditional herbal medicine and cutting-edge pharmaceutical practices forms the backbone of its business model, enabling KPC to sustain substantial revenue through both local and international markets. Diversification is a cornerstone of KPC Pharmaceuticals' strategy. Beyond its traditional medicines, the company has aggressively pursued research and development in the biopharmaceutical sector. This move has expanded its product offerings to include chemical drugs, biotechnology, and over-the-counter products, broadening their appeal to a more extensive clientele. The continuous investment in R&D has led to the development of innovative treatments for ailments such as cardiovascular diseases, cancer, and other chronic illnesses. Additionally, KPC's robust sales network encompasses hospitals, pharmacies, and other healthcare institutions, ensuring widespread distribution and accessibility of its products. Through this diversified portfolio and strong distribution channels, KPC Pharmaceuticals continues to thrive by meeting the evolving needs of the healthcare industry while maintaining its commitment to quality and efficiency.
See Also
What is KPC Pharmaceuticals Inc's Gross Profit?
Gross Profit
3.1B
CNY
Based on the financial report for Sep 30, 2024, KPC Pharmaceuticals Inc's Gross Profit amounts to 3.1B CNY.
What is KPC Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
10%
Over the last year, the Gross Profit growth was -5%. The average annual Gross Profit growth rates for KPC Pharmaceuticals Inc have been -4% over the past three years , -4% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
